Gilead Sciences, Inc
XHAM:GIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gilead Sciences, Inc
XHAM:GIS
|
US |
|
Forbo Holding AG
F:FOZN
|
CH |
|
S
|
Soraya Berjaya Indonesia Tbk PT
IDX:SPRE
|
ID |
Bankruptcy Probability
Gilead Sciences, Inc's probability of bankruptcy is 1%, making a collapse highly unlikely. The solvency score is 55/100 — a warning sign of potential financial weakness.
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Gilead Sciences, Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
195.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.2T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
504B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
363.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
242B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
135.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
128.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
89B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Biogen Inc
NASDAQ:BIIB
|
37.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
80.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Gilead Sciences, Inc's probability of bankruptcy is 1%, making a collapse highly unlikely.
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Gilead Sciences, Inc has total debt of 23.8B USD. This includes both short-term (0 USD) and long-term (23.8B USD) debt.
You can find a full breakdown on its Balance Sheet.